Related Experiment Videos
Future implications for the management of benign prostatic hyperplasia
1Department of Urology, Vrye Universiteit Brussel, Belgium.
European Urology
|January 1, 1994
Summary
Benign prostatic hyperplasia (BPH) treatment lacks standardized evaluation. Alpha-blockers and finasteride are effective, offering immediate symptom relief or prostate volume reduction, respectively.
Area of Science:
- Urology
- Pharmacology
Background:
- Benign prostatic hyperplasia (BPH) presents significant health challenges and costs.
- Current BPH management lacks standardized evaluation parameters.
- Treatment decisions for BPH are complex due to its pathophysiology.
Purpose of the Study:
- To review current BPH treatment options and evaluation criteria.
- To highlight the efficacy of alpha-blockers and finasteride.
- To emphasize the need for further research on other treatments.
Main Methods:
- Review of double-blind, placebo-controlled trials.
- Analysis of International Prostate Symptom Score for evaluation.
- Pharmacological mechanism of action for key treatments.
Main Results:
- Alpha-blockers provide immediate symptom and flow improvement by relaxing smooth muscle.
- Finasteride reduces prostate volume by inhibiting dihydrotestosterone conversion.
- Standardized criteria aid in evaluating treatment efficacy.
Conclusions:
- Alpha-blockers and finasteride are established BPH treatments.
- Further randomized trials are necessary for other medical and nonmedical therapies.
- Standardized evaluation is crucial for effective BPH management.